New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
05:38 EDTTGTXTG Therapeutics reports compelling clinical data from TG-1101 Phase 2 study
TG Therapeutics announced preliminary clinical results from its ongoing Phase 2 study of TG-1101, the company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib. The overall response rate, or ORR, at the first planned efficacy assessment for the 10 evaluable patients was 90%. Of the 28 patients enrolled on study to date, including patients with high risk CLL, no patients have progressed while on the combination, with patients on study now for upwards of 5 months. TG-1101 in combination with ibrutinib was well tolerated in the 28 patients evaluable for safety, with Day 1 infusion related reactions, or IRR, being the most frequently reported adverse event for TG-1101. Updated data presented at the EHA meeting demonstrates an 89% nodal response rate with 8/9 CLL patients now achieving a nodal or partial response on TGR-1202 monotherapy at doses greater than or equal to 800 mg.
News For TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 10, 2014
10:33 EDTTGTXTG Therapeutics price target raised to $33 from $25 at Roth Capital
December 9, 2014
11:15 EDTTGTXTG Therapeutics announces data of TG-1101 in combination with TGR-1202
Subscribe for More Information
December 8, 2014
13:45 EDTTGTXTG Therapeutics says TG-1101 well tolerated in Phase 2 study
Subscribe for More Information
December 7, 2014
16:16 EDTTGTXTG Therapeutics announces results from Phase l study of TGR-1202
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use